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CHAPTER I 
EPILEPSY 
Introduction 
Epilepsy is a collection of neurological disorders which is diagnosed upon the 
occurrence of two or more unprovoked seizures separated by at least 24 hours. Seizures 
arise from excessive and hypersynchronous discharges from large neuronal populations 
in the brain. This is generally thought to occur due to an imbalance between excitation 
and inhibition in the brain. Epilepsy is one of the most common neurological disorders 
and is estimated to affect 0.5-1%of the population worldwide (Hauser 1994). In the 
United States, epilepsy affects nearly 2 million people and costs approximately $15.5 
billion annually. Despite the fact that there is a wide variety of treatment options 
available, over 30% of epilepsy patients are refractory to treatment and continue to 
experience seizures. Additionally, it has been postulated that nearly 10% of Americans 
will experience a seizure at some point in their life. For these reasons, the U.S. Centers 
for Disease Control has deemed epilepsy a public health problem (National Center for 
Chronic Disease Prevention and Health Promotion 2011).  
Epilepsies can be separated into two major classes: partial and generalized. In 
partial epilepsies, seizures begin focally at a cortical site and are typically confined to a 
specific region or neural network but if the aberrant activity spreads widely enough, the 
seizures can become secondarily generalized and involve the entire brain. Partial 
seizures can be further divided depending on whether or not they are accompanied by 
impairments in consciousness; complex partial seizures elicit impairments of 
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consciousness while simple partial seizures do not. Partial epilepsies often result from 
injuries, lesions, or malformations in the brain. In contrast with partial seizures, 
generalized seizures initiate across the entire brain simultaneously with no obvious focal 
origin. Generalized epilepsies can be symptomatic, meaning that they result from a 
known cause such as Lennox-Gastaut syndrome, or they can be idiopathic, meaning that 
there is no known cause. Idiopathic generalized epilepsies are widely believed to have a 
genetic etiology. 
The first line of treatment for epilepsy is typically the use of pharmaceutical 
drugs. There are several anti-epileptic drugs available, but their effectiveness and utility 
vary depending on the type of epilepsy and seizure manifestation. A drug that is 
particularly effective in the treatment of partial seizures could have no effect, or even 
exacerbate absence seizures, while some treatments for absence seizures have no effect 
on partial seizures. Further, there is extensive individual heterogeneity in the 
effectiveness of specific drugs even among patients with the same type of epilepsy and 
seizure manifestations. Alternative treatments for patients who are refractory to 
medication exist and include the ketogenic diet, vagal nerve stimulation, and surgical 
resection of the seizure focus. The ketogenic diet can be effective in both generalized and 
partial epilepsies, but vagal nerve stimulation and surgical resection are typically only 
employed in cases of partial epilepsy. 
Childhood Absence Epilepsy 
 Childhood Absence Epilepsy (CAE) is a form of idiopathic generalized epilepsy 
characterized by the occurrence of non-convulsive absence (formerly referred to as petit 
mal) seizures which are sudden and brief lapses in consciousness typically accompanied 
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by behavioral arrest and a blank stare. In the most severe cases children experience 
hundreds of absence seizures per day which is incredibly disruptive to daily activities—
especially in school aged children. CAE onset is typically between 3 and 12 years of age 
and the disorder is present in 2-8 per 100,000 children under the age of 15 with females 
disproportionately affected (Crunelli 2002; Carney 2005). Interestingly, approximately 
70% of all cases of CAE remit in adolescence although the reason for this is currently 
unclear (Crunelli 2002). 
Absence seizures are accompanied by a characteristic signature on the 
electroencephalogram (EEG)—a bilateral and synchronous spike and wave discharge 
(SWD) with a frequency of ~3 Hz. The interictal EEG does not show any generalized or 
regional slowing, but oftentimes demonstrates brief (1-3 second) runs of generalized 
SWD without any associated clinical changes. Based on extensive studies performed in 
multiple animal models of absence epilepsy, the 3 Hz SWD is thought to arise from 
aberrant oscillations within the thalamocortical circuitry. Rodent models of SWD have 
implicated three major brain regions associated with these aberrant oscillations: the 
somatosensory area of the cerebral cortex and the reticular and ventrobasal nuclei of the 
thalamus. These three structures form an interconnected circuit in which normal sleep 
spindle oscillations occur during sleep (Beenhakker  2009). A schematic of this circuit is 
shown in Figure 1.1 with excitatory projections in green and inhibitory projections in 
red. The mechanism by which these normal oscillations occur is complex and beyond 
the scope of this report, but has been reviewed extensively elsewhere: Beenhakker and 
Huguenard 2009, Neuron. It is thought that the thalamocortical circuitry involved in 
sleep spindle-associated oscillations also pathologically support SWDs and absence 
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seizures that occur during waking. Interestingly, the first line of treatment for CAE, a 
drug called ethosuximide, functions by blocking T-type calcium channels which are 
known to play an integral role in producing the aforementioned thalamocortical 
oscillations. The exact mechanism by which the circuitry malfunctions to produce 
aberrant oscillations is unknown; based on the complexity and interconnectedness of the 
circuitry, several different dysfunctions could feasibly compromise the circuit in a way 
that would support aberrant oscillations. Thus it is possible and maybe even likely that 
multiple different etiologies can lead to absence seizures and there is not one universal 
cause.  
Because seizures are thought to arise from an imbalance in excitatory and 
inhibitory activity in the brain, any mutation that could potentially enhance excitatory 
activity or limit inhibitory activity could lead to a predisposition for epilepsy. While 
most idiopathic generalized epilepsies are assumed to be polygenic, monogenic forms 
have been identified. To date, 17 different mutations in various subunits of the γ amino-
butyric acid type A (GABAA) receptor have been identified in patients with idiopathic 
generalized epilepsy syndromes. At least seven of these mutations have been primarily 
associated with CAE while still more are secondarily associated with absence seizures. 
Because GABAA receptors mediate the majority of fast inhibition in the adult central 
nervous system, it is not surprising that GABAA receptor dysfunction is associated with 
epilepsy.  The subsequent chapter will provide significant background information on 
GABAARs and outline our particular focus within the field of GABAA receptor-
associated idiopathic generalized epilepsies.  
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CHAPTER II 
GABAA RECEPTORS AND EPILEPSY 
Introduction 
GABAA receptors are a family of chloride selective ligand gated ion channels that 
mediate the majority of fast inhibition in the adult central nervous system (Sieghart 
2006). GABAA receptors belong to a larger superfamily of ligand gated ion channels 
called Cys-loop receptors which also includes nicotinic acetylcholine receptors, glycine 
receptors, and serotonin type III receptors (Connolly 2004; Unwin 1993). The GABAA 
receptor gene family is comprised of at least 19 different subunits classified by sequence 
homology into 8 subtypes that can assemble in various combinations to produce 
functional GABAARs: α1-6, β1-3, γ1-3, δ, ε, π, θ, and ρ1-3 (Sieghart 2002). Based on the 
large number of different GABAA receptor subunits, there are seemingly myriad 
different subunit combinations possible, although only a subset of these theoretical 
combinations has been identified in vivo (Mckernan 1996). The cache of possible subunit 
combinations coupled with differing spatial and temporal expression patterns provides 
considerable structural and functional heterogeneity to GABAA receptors. Distinct 
subunit combinations produce distinct receptor isoforms which display highly variable 
properties throughout development and into adulthood (Laurie 1992; Olsen 2009; 
Möhler 2006; Hevers 1998). This topic will be discussed in further detail below. The vast 
majority of GABAA receptors exist as a combination of two α subunits, two β subunits, 
and either a γ or δ (Mckernan 1996; Baumann 2001) subunit arranged as shown in Figure 
2.1A-B. The ε, π, and ρ1-3 subunits are far less common and are generally positioned in 
place of the γ or δ subunit while the θ subunit can assume the position of the β subunit. 
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The morphology of each GABAA receptor subunit includes: a large extracellular domain 
at the N-terminus containing the characteristic disulfide bridge between two cysteine 
residues that creates the “Cys-loop” for which the receptor family is named, four helical 
transmembrane domains termed M1-M4 with the M2 of each subunit lining the ion pore, 
a large intracellular domain between the third and fourth transmembrane domains 
which serves as a site for phospho-regulation, and a very small extracellular C-terminal 
domain (Macdonald 1994; Sieghart 2006; Connolly 2004) as shown in Figure 1C. 
Full activation of GABAA receptors requires the binding of two molecules of the 
neurotransmitter γ-amino butyric acid (GABA)—one at each α/β subunit interface 
(Baumann 2003; Kash 2003). Upon activation of the receptor, the channel opens and 
chloride ions flow down their electrochemical gradient through the pore. In the mature 
brain, this leads to an influx of chloride ions which causes the membrane potential of the 
cell to hyperpolarize and thus serves to inhibit the generation of action potentials. As 
previously mentioned, the wide variety of GABAA receptor isoforms supports extensive 
functional heterogeneity, perhaps best demonstrated by the existence of two distinct 
forms of GABAA receptor mediated inhibition: tonic and phasic (Mody 2001). Tonic 
inhibition is mediated by extrasynaptically localized GABAA receptors largely 
comprised of a δ subunit with an α4 and/or an α6 subunit (Sur 1999), though α5 
containing receptors lacking a δ subunit are known to function extrasynaptically as well 
(Caraiscos 2004). These receptors are continuously activated by low levels (1 M) of 
ambient GABA typically overflowing from the synaptic cleft. The properties of these 
receptors are conducive to persistent extrasynaptic activation as they are highly sensitive 
to GABA, activate relatively slowly, and desensitize minimally (Mtchedlishvili 2006).  
8 
 
 
  
9 
 
The functional role of tonic inhibition is the regulation of neuronal excitability. 
Conversely, phasic inhibition is mediated by synaptic GABAA receptors most often 
containing a γ subunit with α1, α2, and/or α3 subunits. Unlike their extrasynaptic 
counterparts, synaptic GABAA receptors are transiently activated by much higher (1 
mM) concentrations of GABA released from the presynaptic neuron into the synaptic 
cleft. These receptors differ from those mediating tonic inhibition to allow for fast 
transmission of a fleeting signal and are thus less sensitive to GABA, activate rapidly, 
and desensitize extensively (Haas 1999). The short-lived activation of these receptors 
produces a transient inhibitory post-synaptic current (IPSC) which functions to 
transform presynaptic GABA release into a post-synaptic signal (Farrant 2005; Nusser 
1998). The remainder of this chapter will focus on the most predominant subtype of 
synaptic receptors: those containing the α1 subunit. The distinct receptor properties and 
known roles of the α1 subunit as well as important findings from α1 subunit knockout 
mice and recently discovered epilepsy associated mutations in the α1 subunit are all 
discussed at length below.    
Biophysical Properties of the α1 Subunit Relative to Other Synaptic α Subunits 
The α1 subunit is the most predominant α subunit in the adult brain and is most 
often assembled into the α1β2γ2 isoform comprising 60% of all GABAA receptors 
(Möhler 2006). Further heterogeneity exists among synaptic receptors as the specific α 
subtype influences biophysical properties of GABAA receptors including GABA 
sensitivity and the rates of activation, deactivation, and desensitization (Gingrich 1995; 
Eyre 2012; Picton 2007; Lavoie 1997; Böhme 2004). The primary strategy employed to 
determine the contribution of each α subunit to a particular property is to express 
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different α subunits with the same β and γ subunit partners in heterologous cells and 
explore the various properties. One such property, GABA sensitivity, is defined by the 
concentration of GABA that is required to produce a given response. A common 
measure of GABA sensitivity is the concentration of GABA required to elicit a half-
maximal response in a given receptor subtype, known as the EC50. A low EC50 
indicates higher sensitivity and vice versa. The activation rate of a particular GABAA 
receptor is the rate at which receptor current increases from 10% to 90% of the maximal 
or peak current and the deactivation rate is the rate at which current amplitude 
decreases after GABA is removed.  The desensitized state of the receptor is a high 
affinity state in which GABA is bound but the ion channel is closed, thus the 
desensitization rate is the rate at which the response diminishes in continued presence of 
GABA. Each of the biophysical properties defined above influence the shape and time 
course of GABAA receptor mediated IPSCs, thus the α subunit within the receptor in 
large part dictates the properties of inhibitory currents. The biophysical properties of α1 
containing GABAA receptors relative to other synaptic α subunits are summarized in 
Table 2.1 (Gingrich 1995; Eyre 2012; Picton 2007; Lavoie 1997).  
Interestingly, the properties of GABAA receptor mediated IPSCs are known to 
change throughout development (Okada 2000; Dunning 1999)—namely the decay 
kinetics which are heavily influenced by the deactivation and desensitization rates of the 
receptors (Jones 1995; Ortinski 2004). In fetal and early post-natal development, GABAA 
receptor mediated IPSCs decay relatively slowly; later in development, the IPSCs decay 
much faster. The timing of this change coincides with the timing of a well-established 
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GABA Sensitivity α1  >  α2  >  α3
Activation Rate α2  >  α1  >  α3
Deactivation Rate α1  >  α2  >  α3
Desensitization Rate α1  =  α2  >  α3
Table 2.1: Relative Biophysical Properties Conferred by Synaptic α Subunits
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developmental change in GABAA receptor α subunit expression (Laurie 1992; 
Hashimoto 2009; Fritschy 1994). Early in development, the  α2 and α3 subunits 
predominate but soon after birth their expression begins to wane while the expression of 
the α1 subunit steadily increases to become the most abundant α subunit by  postnatal 
day 12 in mice (Laurie 1992). A comparison of juvenile and mature GABAA receptor 
mediated IPSCs is shown in Figure 2.2. Given that the identity of the α subunit impacts 
IPSC properties, it is feasible that the developmental changes in α subunit expression 
and IPSC decay causally linked. Indeed, it has been shown that in mice lacking the α1 
subunit juvenile IPSC kinetics persist into adulthood (Bosman 2005; Vicini 2001; 
Goldstein 2002). The functional role of this developmental switch in α subunit 
expression and the concomitant change in IPSC kinetics is currently not well 
understood.  
 Findings From α1 Subunit Knockout Mice 
In 2001, transgenic mice lacking the α1 subunit of the GABAA receptor were 
generated and studies have shown that the loss of the α1 subunit results in a 50-60% 
decrease in the total number of GABAA receptors in the brain (Vicini 2001; Sur 2001). 
Consistent with this finding, the expression of the β2/3 and γ2 subunits—the most 
common binding partners of the α1 subunit—is also decreased in α1 knockout mice 
(Kralic 2006; Kralic 2002). Given that the α1 subunit is the most abundant subunit and its 
loss results in a loss of the majority of GABAA receptors in the brain, it is very surprising 
that these animals are viable and lack any obvious phenotypic abnormalities aside from 
a slight handling-induced tremor. The fact that the mice are overtly normal could 
suggest that changes occur within the GABAA receptor system to compensate for the 
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loss of α1. Indeed, post-transcriptional increases in the total expression of the other α 
subunits have been observed (Kralic 2002; Kralic 2006), but changes in surface 
expression have not been explored. The nature and extent of the compensation in total 
expression seems to vary among brain regions and has not been systematically 
quantified in the entire brain. One study suggests that neurons upregulate the subunits 
they normally express rather than expanding their subunit repertoire (Kralic 2006), 
which is consistent with a post-transcriptional mode of upregulation. The consequences 
of these compensatory changes are not completely understood, but α1 knockout mice 
fail to develop mature IPSC kinetics (Bosman 2005; Vicini 2001; Goldstein 2002) and 
exhibit a lower threshold for pharmacologically induced seizures (Kralic 2002). This 
could indicate a decrease in inhibitory tone, although it was reported that α1 knockout 
mice did not experience spontaneous seizures (Sur 2001). However, it is important to 
note that these conclusions were drawn by visual inspection only rather than EEG 
analysis. Certain types of seizures, such as absence seizures, result in very subtle 
alterations in behavior that are difficult to detect even in a human, much less a mouse. 
Thus it is possible that these animals did have seizures but did not display any easily 
detectable seizure behavior. 
The α1 Subunit and Epilepsy      
Because GABAA receptors are the primary source of inhibition in the central 
nervous system, it is not surprising that several mutations in various GABAA receptor 
subunits have been identified in patients afflicted with idiopathic generalized epilepsy 
syndromes such as childhood absence epilepsy and juvenile myoclonic epilepsy 
(Macdonald 2006; Macdonald 2004; Macdonald 2010a). Epilepsy is a large collection of 
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syndromes diagnosed upon the occurrence of two or more unprovoked seizures and 
may be classified as idiopathic generalized epilepsy if the cause is thought to be genetic 
and the seizures appear to involve the entire brain simultaneously with no obvious focal 
origin. Most idiopathic generalized epilepsies are thought to be multigenic which 
renders animal modeling fairly difficult, but the identification of monogenic forms has 
permitted the generation of animal models based on human disease associated 
mutations. To date there have been four mutations identified specifically in the α1 
subunit in human patients suffering from idiopathic generalized epilepsy. Two of these 
mutations, K353delins18X and D219N (Lachance-Touchette 2011), were only recently 
reported and have not been fully characterized. The other two however, A322D 
(Cossette 2002) and S326fs328X (Maljevic  2006), have been studied in somewhat more 
detail.  
α1(K353delins18X) Mutation The α1(K353delins18X) mutation was identified in 
1 unaffected and 3 affected individuals with idiopathic generalized epilepsy exhibiting 
generalized tonic-clonic seizures. These seizures manifest as a sudden tensing of skeletal 
muscles followed by rapid contractions and relaxations resulting in characteristic 
convulsions (Pamplona 1989). This mutation involves the insertion of 25 base pairs into 
intron 10 which interrupts mRNA splicing and causes the retention of intron 10 in the 
transcript. This leads to an 18 amino acid insertion into the protein as well as the 
truncation of the fourth transmembrane domain due to a premature stop codon. Work in 
heterologous expression systems revealed that the protein is localized to the 
endoplasmic reticulum with complete loss of cell surface expression. In agreement with 
these findings, GABA mediated currents were absent in these cells (Lachance-Touchette 
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2011). The fate of the mutant protein and the mechanism by which the 
α1(K353delins18X) mutation leads to epilepsy is yet to be determined.      
α1(D219N) Missense Mutation The D219N missense mutation was identified in 4 
of 5 affected individuals with idiopathic generalized epilepsy in a French-Canadian 
family exhibiting idiopathic generalized epilepsy or febrile seizures—so named due to 
their coincidence with fever (Pamplona 1989). Two of the four individuals with febrile 
seizures also reported a single generalized tonic clonic seizure. Studies conducted in 
heterologous expression systems indicate that surface expression of the mutant subunit 
is reduced as compared to wild type (WT) α1 subunit, consistent with observations of 
decreased GABA evoked peak current amplitudes. Additionally, α1(D219N) subunit 
containing receptors were shown to desensitize more rapidly than WT α1 subunit 
containing receptors (Lachance-Touchette 2011). Further studies characterizing the 
effects of this mutation both in vitro and in vivo will be required to elucidate the 
mechanism by which it promotes the development of epilepsy. 
α1(A322D) Missense Mutation The A322D missense mutation was identified in 8 
affected individuals within a large French-Canadian family suffering from a type of 
idiopathic generalized epilepsy called juvenile myoclonic epilepsy. Myoclonic seizures 
are characterized by sudden, brief, involuntary jerks of the arms or legs (Pamplona 
1989). This mutation is autosomal dominant and results in the insertion of a charged 
aspartate residue in place of a highly conserved alanine within the M3 domain (Cossette 
2002; Macdonald 2006; Macdonald  2004; Macdonald 2010a). Experiments in 
heterologous cells indicate that this mutation disrupts the insertion of M3 into the lipid 
bilayer which results in its retention in the endoplasmic reticulum and subsequent 
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partial degradation through endoplasmic reticulum associated degradation (ERAD). 
(Gallagher 2005; Macdonald 2004; Macdonald 2006; Macdonald 2010a) However, the 
mutant subunit is not completely degraded as total and surface mutant protein is 
detectable, albeit at significantly lower levels than the WT α1 subunit (Gallagher 2005; 
Macdonald 2004; Macdonald 2006; Macdonald 2010a). It has also been postulated that 
the α1(A322D) mutation exerts a dominant negative effect by oligomerizing with and 
trapping WT subunits in the endoplasmic reticulum which are then subject to ERAD 
(Ding 2010; Macdonald 2006). Consistent with reduced surface expression, the peak 
GABA evoked current through receptors containing the α1(A322D) subunit was reduced 
88% (Gallagher 2004). In the mutant receptors, open time of the channel was 
considerably reduced. Additionally, α1(A322D) subunit containing receptors exhibited 
substantially reduced sensitivity to GABA with a nearly 100-fold increase in GABA 
EC50 (Gallagher 2004).  
α1(S326fs328X) Frameshift Mutation The α1(S326fs328X) mutation is an 
autosomal dominant de novo mutation identified in a patient with childhood absence 
epilepsy. In contrast to the previously mentioned seizure types, absence seizures are not 
associated with any sort of convulsions or motor movements. Rather, they are 
characterized by sudden brief lapses in consciousness often accompanied by a blank 
stare (Pamplona 1989). A single base pair deletion leads to a frameshift and premature 
termination codon (PTC) in the eighth exon which corresponds to the third 
transmembrane domain of the protein (Maljevic 2006). The PTC has been shown to 
induce nonsense mediated decay (NMD) of the mutant mRNA, albeit incomplete. 
Mutant mRNA that escapes NMD is subsequently translated into truncated protein 
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which is retained in the ER and subjected to ERAD (Kang 2009; Macdonald 2010b). 
Thus, the α1(S326fs328X) mutant subunit is not incorporated into the cell membrane and 
GABA evoked currents are absent (Kang 2009; Maljevic 2006). Based on these findings, it 
is thought that the epilepsy phenotype is a result of haploinsufficiency in the WT α1 
gene. This raises the intriguing possibility that heterozygous α1 knockout animals could 
serve as a model for this disease. Indeed, we recently revealed through EEG analysis 
that heterozygous α1 knockout mice do in fact experience absence seizures (Arain 2012). 
This may explain why it was previously reported that α1 knockout mice did not exhibit 
an epileptic phenotype as mentioned above. The seizures were greatly attenuated by 
treatment with ethosuximide, the most commonly prescribed drug for absence seizures 
in human patients. This represents a novel model of absence epilepsy based on a 
mutation identified in a human epilepsy patient that is face, construct, and predictively 
valid.  
Conclusion 
GABAARs are a heterogeneous population of receptors and their properties are 
heavily influenced by their α subunit composition. The α1 subunit is the most 
predominant subunit in the adult brain and is largely responsible for the maintenance of 
inhibitory tone in the CNS. As evidenced by the consequences of the dysfunction or loss 
of the α1 subunit, it also seems to be involved in epilepsy susceptibility. The transgenic 
α1(A322D) knock-in and α1 knockout mouse lines that our group focuses on represent 
the first mouse models of genetic epilepsy based on mutations in the α1 subunit 
identified in human epilepsy patients. These two mutations were both identified in 
patients suffering from generalized epilepsy, but their seizure phenotypes were distinct. 
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Based on our preliminary analyses, the epileptic phenotypes of the two mouse lines also 
differ. By dissecting the similarities and differences in pathogenesis behind these two 
models, we aim to identify common themes among all generalized epilepsies and also 
delineate important differences that contribute to distinct disease manifestations. While 
epilepsy is an exceptionally complicated and heterogeneous condition, the advent of 
animal models reflecting specific disease-associated mutations in GABAARs represents a 
promising new avenue for advancing our understanding of the pathogenesis of 
generalized epilepsy. The majority of my work has been in the heterozygous α1 
knockout model of CAE; this work will be discussed in detail in subsequent chapters. 
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CHAPTER III 
EXPERIMENTAL STRATEGY 
Rationale 
 In 2006, a heterozygous de novo frameshift mutation in the α1 subunit of the 
GABAAR was identified in a patient with childhood absence epilepsy (Maljevic 2006). 
Subsequent analysis of this mutation in vitro revealed that the mutation caused complete 
elimination of the mutant α1 subunit protein via nonsense mediated decay of the mutant  
mRNA and endoplasmic reticulum associated degradation of the mutant protein (Kang 
2009). Thus, it is thought that the patient’s epileptic phenotype arose as a result of 
haploinsufficiency of the wild type GABAA receptor α1 subunit. This indicated that 
heterozygous α1 knockout mice may serve as a model for studying CAE. Thus we 
generated α1 knockout mice and characterized the heterozygous animals to determine if 
they recapitulate an epilepsy phenotype. Indeed, EEG analysis revealed that the 
heterozygous α1 knockout animals exhibit an absence epilepsy phenotype characterized 
by brief 6-8 Hz SWD often accompanied by behavioral arrest (Arain 2012). Aberrant 
oscillations within thalamocortical circuitry are most widely associated with absence 
seizures and SWDs and the cortex is postulated to play a leading role (Polack 2007). 
Interestingly, the epileptiform events in the heterozygous α1 knockout mice were 
greatly attenuated by treatment with ethosuximide, the most commonly prescribed drug 
for the treatment of absence seizures in humans. Thus, heterozygous α1 knockout mice 
serve as a model for absence epilepsy that is construct, face, and predictively valid 
(Arain 2012).  
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It has been reported that homozygous α1 knockout animals express 60% less 
GABAARs than wild type mice (Kralic 2002). Additionally, multiple studies have shown 
that the complete loss of the α1 subunit is compensated for, in part, by increased 
expression of other GABAA receptor subunits—namely α2 and α3 (Kralic 2006; Kralic 
2002). However, few studies have assessed whether or not compensation occurs in 
heterozygous α1 subunit knockout mice, nor has there been any work specifically 
measuring levels of GABAA receptor subunit proteins expressed on the cell surface. 
Because only receptors expressed on the surface of cells mediate GABAergic currents, 
surface expression of GABAA receptor subunit proteins is very important to measure; 
this is the receptor population that dictates cellular GABAergic physiology.  Likewise, it 
is well established that different α subunits confer distinct receptor properties and 
distinct inhibition (Eyre 2012). Thus, if compensation occurs in the heterozygous 
animals, physiological properties of the cells could be altered which may in turn offer 
insight into the pathophysiology of absence epilepsy. 
Our overarching goal was to investigate the basis for the absence phenotype in 
the heterozygous α1 knockout animals by assessing the expression of various GABAA 
receptor subunit proteins using biochemical techniques and to determine whether or not 
the heterozygous α1 knockout animals exhibited alterations in cortical GABAergic 
physiology.   
Experimental Strategy 
Using heterozygous α1 knockout (α1HetKO) mice and wild type mice as 
controls, we performed the following experiments. Employing brain slice biotinylation 
and quantitative Western blotting, we measured both surface and total expression of 
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GABAA receptor proteins. We first determined the effect of α1HetKO on the total and 
surface expression of functional GABAA receptors Using β subunit expression—all 
known functional GABAA receptors contain two β subunits. Next we quantified the 
surface and total expression of the α1 subunit as well as the other synaptic α subunits, 
α2 and α3.  
 Upon observing changes in expression of subunit proteins, we then attempted to 
identify the mechanism by which these changes occurred. We determined if the changes 
were a result of altered gene expression by measuring mRNA via quantitative real time 
polymerase chain reaction (qRT-PCR). We also used a recently described 
electrophysiological technique (Kotowski 2011) in combination with the dynamin-
mediated endocytosis inhibitor, dynasore, to assess whether or not α1HetKO animals 
exhibited altered endocytosis or recycling of their surface-resident GABAA receptors.    
Lastly, we sought to determine if the changes we observed in GABAA receptor 
expression using biochemical techniques had any effect on neuronal GABAergic 
physiology in layer VI of the cortex. This is the layer that projects to the thalamus and is 
thought to play an integral role in aberrant thalamocortical oscillations. 
In these studies, we identified changes in GABAA receptor expression and 
physiology in animals exhibiting an absence epilepsy phenotype. The results reported 
and discussed in the following chapters may serve to elucidate pathophysiological 
mechanisms by which GABAA receptor dysfunction could lead to the development of 
absence epilepsy.  
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CHAPTER IV 
METHODOLOGY 
Animals 
 All procedures and protocols performed here were approved by the Vanderbilt 
University Animal Care and Use Committee. Mice were housed in a temperature and 
humidity controlled environment with ad libitum access to food and water on a 12:12 
light:dark cycle. In 2001, Vicini et al. produced a line of transgenic mice with loxP 
sequences flanking exon 9 of the GABAA receptor α1 subunit (Vicini 2001). Using these 
mice, we subsequently generated global α1 subunit deletion mice and bred them into a 
congenic C57BL/6J background (Arain 2012). We crossed heterozygous α1 knockout 
mice with wild type mice and used the female offspring between ages P33-P37. These 
mice were shown to have frequent absence seizures in our previous EEG studies. The 
genotypes of the mice used for experiments were determined using PCR. 
Brain Slice Preparation 
 Solutions used for brain slice preparation and incubation are listed in Table 
4.1.The mice were anesthetized using isoflurane and then sacrificed. The brains were 
rapidly dissected and moved to ice cold cutting solution for sectioning. In the 
biotinylation experiments, three to four 300 µm midline sagittal slices were made using a 
vibratome (Leica VT1200S). The slices were then incubated in artificial cerebrospinal 
fluid (aCSF) and bubbled with 100% O2 at 0°C and biotinylated less than one hour after 
slices were cut. For electrophysiology experiments, 300 µm coronal slices containing the 
somatosensory cortex were sectioned in cutting buffer and then incubated in aCSF 
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which contained 26 mM NaHCO3 and 2 mM MgCl2 and bubbled with 95%O2/5%CO2 at 
36°C for 30 minutes (Schofield 2009; Zhou 2011; Moyer 1998). The slices were then 
incubated at room temperature for at least one hour before recording. 
 
Table 4.1: Brain Slice Solutions 
Biotinylation  Electrophysiology 
Cutting aCSF Cutting 
Reagent mM Reagent mM Reagent mM 
Sucrose 210 NaCl 126 Sucrose 214 
NaCl 20 KCl 2.5 CaCl2 0.05 
KCl 2.5 NaH2PO4 1.25 KCl 2.5 
NaH2PO4 1.2 CaCl2 2 NaH2PO4 1.25 
MgCl2 1 MgCl2 1 MgSO4 10 
D-glucose 10 D-glucose 10 NaHCO3 24 
pH 7.4 pH 7.4 D-glucose 11 
        pH 7.4 
 
     
Brain Slice Biotinylation 
 Brain slice biotinylation has been described previously for the quantification of 
protein expressed on the cell surface in intact brain slices (Goodkin 2008; Robertson 
2010; Vithlani 2011). After cutting, the brain slices were incubated at 4°C for 45minutes 
in aCSF containing 1 mg/mL of the membrane-impermeable biotinylation reagent 
sulfosuccinimidyl-2-(biotinamido)-ethyl-1,3’-dithiopropionate (Sulfo-NHS-SS-biotin, 
Thermo Scientific). Next, the biotinylation reaction was quenched by washing the slices 
with aCSF containing 0.1 M glycine. The cortices were dissected from the slices and 
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subsequently sonicated in radioimmunoassay solution (RIPA, 20 mM Tris pH 7.4, 1% 
TritonX-100, 250 mM NaCl) containing 1:100 protease inhibitor cocktail (Sigma Aldrich) 
and 0.5% deoxycholate and 0.1%SDS. 
 Protein concentrations were measured using a bicinchoninic acid-based assay 
(Thermo Scientific). 150 µg of cortical protein lysate was incubated with 100 µL 
neutravidin beads (Thermo Scientific) in a total volume of 500 µL RIPA overnight at 4°C 
in order to isolate the biotinylated proteins from the cell surface. In order to confirm that 
the neutravidin beads did not become saturated with biotinylated protein, we incubated 
the beads with increasing concentrations of cortical protein lysate and subsequently 
observed proportional increases in the amount of biotinylated material recovered from 
the beads. After the overnight incubation, the beads were centrifuged to form a pellet 
which was then washed three times with RIPA. The biotinylated protein was then eluted 
from the beads using 60-80 µL of Laemmli sample buffer (BioRad) containing 5% β-
mercaptoethanol to yield the surface protein fraction. The surface fraction was then 
analyzed using Western blot. To verify that the biotinylation reagent was selective for 
surface membrane proteins, we determined the amount of the cytoplasmic protein 
GAPDH present in samples purified with the neutravidin beads versus unpurified 
samples.      
Antibodies and Western Blots 
 Primary and secondary antibodies used in the analysis of Western blots are listed 
in Table 4.2 and Table 4.3, respectively. Total and surface proteins were separated on 
10% SDS-PAGE gels and subsequently electrotransferred onto nitrocellulose 
membranes. To verify linearity of detection, increasing concentrations or volumes of 
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protein were added to the gel (5-10-20 µg from the total fraction, and 5-10-20 µL of 
surface fraction eluted from either the neutravidin or protein G beads). We excluded 
blots in which the signal from each protein did not increase proportionally with the 
amount loaded from our analyses. Likewise, we confirmed that α1HetKO did not affect 
the total or surface expression of our loading control protein, the α subunit of the 
Na+/K+ ATPase.  Before exposing the membrane to antibody, nonspecific binding was 
blocked using 5% nonfat dry milk in Tris buffered saline containing 0.1%Tween at pH 
7.4. Blots were incubated in primary antibody overnight at 4°C and then with secondary 
antibody at room temperature for one hour. The blots were then imaged on an infrared 
fluorescent imaging system (Licor). 
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
  Relative abundances of the α1 and α3 subunits of the GABAA receptor mRNA 
were measured in mouse cortices from wild type and heterozygous α1 subunit knockout 
mice as described previously (Zhang 2011). We isolated total RNA from freshly 
dissected cortices using a silica membrane column (Purelink). We produced 
corresponding cDNA from 200 ng of RNA using reverse transcriptase and random 
hexamers (Applied Biosystems). qRT-PCR was performed with an Applied Biosystems 
7900 system with TaqMan universal Master Mix, FAM-labeled probes (Applied 
Biosystems) for the α1 subunit (Mm00439046, spanning Exon 9 which is deleted in the 
transgene) and the α3 subunit (Mm01294271). We used a VIC-labeled probe (Applied 
Biosystems) for beta-actin, our endogenous control (4352341E). The following RT-PCR 
conditions were used for these experiments: 10 minutes at 90°C, 40 cycles of: 15 seconds 
at 95°C for denaturation and 60 seconds at 60°C for annealing and extension. After 
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verifying that the heterozygous loss of the α1 subunit did not alter the expression of the 
endogenous control, we used the ΔΔCt cycle threshold method to determine the effect of 
the heterozygous α1 subunit knockout on the expression of α1 and α3 subunit mRNA 
when normalized to expression of beta-actin mRNA.  
Electrophysiology 
 Using an upright Nikon eclipse FN-1 IR-DIC microscope, pyramidal neurons 
residing in layer VI in the S1/S2 region of the somatosensory cortex were identified for 
whole-cell patch clamp recordings. Neurons located in the cortical layer above the white 
matter and exhibiting a characteristic apical dendrite and large soma were chosen for 
these recordings. The solution within the patch pipette contained the following in mM: 
135 CsCl, 10 EGTA, 10 HEPES, 5 ATP-Mg, and 5 QX-314 at a pH of 7.3 and osmolarity 
within the range of 290-295 mOsm (Schofield 2009). The bath solution was aCSF which 
also contained 20 M NBQX to block AMPA and kainite receptors. Filled electrodes 
exhibited 2-4 M resistances; serial resistance was monitored throughout the 
experiments and we discarded recordings that had greater than 25 M  or 20% change 
in serial resistance during the recording. The data were collected with a MultiClamp 
700B amplifier and Clampexx 10.2 software, filtered at 2 kHz, and digitized at 20 kHz 
using a Digidata 1440A analog to digital converter (Molecular Devices Inc.). All data 
were recorded with compensation for series resistance (70%) and cell capacitance. 
 Miniature inhibitory post synaptic currents (mIPSCs) were recorded in bath 
solution also containing 1 M tetrodotoxin (Sigma-Aldrich) to block sodium channels 
and thus action potentials. Recordings were made in voltage clamp mode with the cells 
clamped at -60 mV for at least 20 minutes. The mIPSCs were identified offline 
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automatically using Clampfit 10.2 and confirmed visually. Peak mIPSC amplitudes, 
inter-event intervals, and 10-90% rise times were also identified. We fit the current decay 
of each mIPSC to a single exponential and calculated the decay constant (). mIPSCs 
having peak amplitudes less than 1 pA,  less than 1 ms or greater than 1000 ms, or rise 
time greater than 10 ms were excluded from our analyses. Cumulative histograms were 
constructed for all mIPSCs from all neurons of the same genotype for peak amplitudes, 
event intervals, rise times, and decay constants. We also calculated the mean peak 
amplitude, event interval, rise time, and decay constant from each individual neuron 
and averaged these among cells of the same genotype. We then compared these 
averaged values from heterozygous α1 knockout and wild type neurons using a two 
tailed t-test. Additionally, averaged mIPSC tracings were created for each neuron and 
the current decay of these average traces were fit with one or two time constants (1 and 
2) and then calculated the weighted decay constant (w) using the following equation: 
(1 x A1 + 2 x A2)  (Α1 + A2) where A1 and A2 are the amplitudes corresponding to 1 
and 2, respectively. 
Receptor Endocytosis and Recycling 
 To determine the effect of heterozygous loss of the GABAA receptor α1 subunit 
on GABAA receptor endocytosis and recycling from the plasma membrane in intact 
brain slices, we adapted a previously published protocol used to measure dopamine 
receptor endocytosis (Kotowski 2011). First, we recorded mIPSCs as described above for 
a five minute baseline period. Next, we added dynasore (3-hydroxy-naphthalene-2-
carboxylic acid), an effective inhibitor of dynamin-dependent endocytosis, and recorded 
mIPSCs for an additional 20 minutes. The final concentrations of dynasore and DMSO 
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were 80 M and 0.2%, respectively. mIPSC peak amplitudes were averaged in one 
minute epochs before and after treatment with dynasore, and time-dependent changes 
in mIPSC amplitudes were compared between wild type and heterozygous GABAA 
receptor α1 subunit knockout neurons. 
Data Analysis and Statistics 
Statistical analyses were performed with the R 2.12.2 Statistical Package for 
Windows (R Foundation for Statistical Computing). All of the results presented herein 
are the mean ± standard error. The statistical significance of averaged values was 
assessed using single sample or independent sample t-test as appropriate. Additionally, 
we used the two sample Kolmogorov—Smirnov (K-S) test to compare distributions of 
wild type and heterozygous α1 knockout mIPSC peak amplitudes, event intervals, 10-
90% rise times, and decay constants. P values less than 0.05 were considered to be 
statistically significant. 
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CHAPTER V 
RESULTS 
α1HetKO Causes a Modest Reduction in Functional GABAA Receptor Expression 
 Because all known functional GABAA receptors contain two β subunits, β 
subunit expression can be used as a measure of functional GABAA receptor expression. 
We measured the total and surface expression of the β1, β2, and β3 subunits in the 
cortex of WT and α1HetKO mice. We did not detect any total or surface expression of 
the β1 subunit in the WT or α1HetKO samples (not shown). However, we were able to 
reliably detect recombinantly expressed β1 subunits with our immunoblots; this 
indicates that our methods for detecting the β1 subunit protein are effective and that the 
β1 subunit is not abundantly expressed in the cortex of mice at this age. α1HetKO 
caused a reduction to 75 ± 8% as compared to WT in total β2 expression (N=8, P=0.019 
vs. 100%) and a reduction to 78 ± 5% in surface expression of β2 as compared to WT 
(N=8, P=0.003 vs. 100%, Figure 5.1 A). Conversely, α1HetKO did not alter the total (102 
± 8%, N=6, P=0.796 vs. 100%) or surface (96 ± 5%, N=8, P=0.458 vs. 100%) expression of 
the β3 subunit when compared to WT (Figure 5.1 B). α1HetKO did not alter β3 
expression and caused only a modest reduction in β2 expression, suggesting only a 
small reduction in functional GABAA receptor expression despite the heterozygous loss 
of the most abundant subunit. This finding is consistent with previous reports of 
compensatory upregulation of the expression of other GABAA receptor subunits in 
homozygous α1 subunit knockout mice. We next examine the expression of synaptic α 
subunits to determine if compensation occurs in the heterozygous condition as well. 
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α1HetKO Increases the Surface : Total Expression Ratio of the α1 Subunit  
 A previous report indicated that α1HetKO decreased total expression of the α1 
subunit protein (Kralic 2006), but there have been no studies investigating the effect of 
α1HetKO on the surface expression of the α1 subunit. Because only receptors expressed 
on the surface of cells mediate GABAergic currents, this is the receptor population that 
dictates cellular GABAergic physiology. Thus, in order to understand how α1HetKO 
could alter cellular physiology and precipitate epilepsy, it is vital to measure the effects 
of α1HetKO on surface expression of GABAA receptor subunits. Consistent with 
previous results (Kralic 2002), we found that α1HetKO decreased total α1 expression to 
62 ± 8% of WT expression (N=8, P=0.002 vs. 100%, Figure 5.2). Yet, α1HetKO elicited a 
significantly smaller reduction of α1 subunit protein expressed on the cell surface (89 ± 
5%, N=5, P=0.015 vs. total expression, Figure 5.2). These results indicate that the cortex 
of α1HetKO mice may partially compensate for the heterozygous loss of α1 by 
increasing the surface : total expression ratio. We next explored whether or not other 
synaptic α subunits—namely α2 and α3—participated in compensation in the α1HetKO 
mice. 
Expression of the α3 But Not the α2 Subunit is Increased in α1HetKO Cortex 
 Wild type cortical synapses express the α2 and α3 subunits in conjunction with 
the α1 subunit, though α1 is by far the most abundant  (Heller 2012; Hutcheon 2004; Yu  
2006). Thus, we investigated whether or not α2 and α3 could compensate for the loss of 
α1 by measuring the total and surface levels of these two subunits in cortices from WT 
and α1HetKO mice.  
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 α1HetKO did not elicit any significant changes in the total (105 ± 4%, N=4, 
P=0.389, Figure 5.3 A) or surface (117 ± 7%, N=5, P=0.081, Figure 5.3 A) expression of the 
α2 subunit as compared to WT. Conversely, α1HetKO significantly increased the 
expression of the α3 subunit in both the surface and total fractions. Total α3 expression 
was increased to 138 ± 18% that of WT (N=10, P=0.016 vs. 100%, Figure 5.3 B) while α3 
surface expression increased to 174 ± 24% that of WT (N=7, P=0.020 vs. 100%, Figure 5.3 
B). These findings indicate that α1HetKO also partially compensates for the loss of the 
α1 subunit by increasing both the total and surface expression of the α3 subunit protein. 
We next attempted to identify the mechanism by which the compensatory changes 
identified thus far occur. 
α1HetKO Does Not Alter the Expression of WT α1 or α3 Subunit mRNA 
 Using quantitative real time PCR (qRT-PCR), we measured levels of WT α1 and 
α3 subunit mRNAs in the cortices from WT and α1HetKO mice. We confirmed that 
α1HetKO did not alter the expression of actin, our endogenous control mRNA used for 
normalization. α1HetKO expressed 52 ± 7% (N=6, P=0.750 vs. 50%, not shown) that of 
WT α1 subunit mRNA, consistent with the heterozygous deletion of the α1 subunit 
gene. This indicates that α1HetKO does not compensate for the loss of α1 by 
upregulating the expression of the remaining WT allele. Likewise, we observed no 
significant changes in the expression of α3 subunit mRNA (90 ± 7%, N=6, P=0.230 vs.  
100%, Figure 5.4). These results indicated a post-transcriptional mode of upregulation 
may be responsible for the compensatory increases in α1 and α3 protein expression. We 
next examined whether α1HetKO altered endocytosis and recycling of GABAA receptors 
from the cell surface as a possible mode of upregulation. 
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α1HetKO Alters the Endocytosis and Recycling of GABAA Receptors 
 Recently, dopamine receptor endocytosis and recycling was measured using 
brain slice patch clamp electrophysiology in conjunction with the administration of 
dynasore, an effective inhibitor of dynamin-dependent endocytosis (Kotowski 2011). 
Previous reports indicate that the surface expression of GABAA receptors is regulated by 
dynamin-dependent endocytosis (Kittler 2000; Kittler 2004; Kittler 2005; Kittler 2008). 
Therefore, we measured the effects of dynasore on GABAergic currents in brain slices 
from WT and α1HetKO mice. We recorded mIPSCs from layer VI pyramidal neurons for 
a baseline period of five minutes and then added 80 µM dynasore to the bath solution 
and recorded mIPSCs for an additional 20 minutes. The application of dynasore elicited 
a time-dependent increase in the mIPSC amplitude of WT neurons but had no 
significant effect on those of α1HetKO neurons (Figure 5.5 A). After 20 minutes of 
dynasore treatment, mIPSC peak amplitude in WT was 126 ± 9.4% of baseline (N=5) 
while mIPSC peak amplitude in α1HetKO neurons was only 87 ± 7.9% of baseline (N=5, 
P=0.014 α1HetKO vs. WT effect of dynasore, Figure 5.5 B). These data suggest that WT 
neurons exhibit a higher rate of GABAA receptor insertion into the membrane from the 
cytoplasm and that α1HetKO reduce the amount of GABAA receptors in early 
endosomes through a decreased rate of baseline endocytosis.  
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α1HetKO Alters Synaptic GABAergic Currents  
 Recall from Chapter II that the identity of the α subunit within a GABAA receptor 
in large part dictates the biophysical properties of the receptor and thus the properties of 
inhibitory currents of the neuron in which they are expressed. In particular, GABAA 
receptors containing the α3 subunit exhibit reduced sensitivity to GABA, increased rise 
times, and slower current decay kinetics as compared to α1 containing receptors. 
Because our biochemical experiments indicated a large increase in α3 subunit expression 
in the α1HetKO mice, we investigated the effects of α1HetKO on the properties of 
synaptic GABAergic currents in the cortex.  Specifically, we recorded mIPSCs from layer 
VI pyramidal neurons in the somatosensory cortex of brain slices from WT and 
α1HetKO mice (Figure5.6 A). Recall from Figure 1.1 that this region is thought to initiate 
the aberrant oscillations characteristic of absence seizures (Polack 2007) and projects to 
the thalamus which is thought to sustain and facilitate the generalization of the 
oscillations (Paz 2011). 
 We found that α1HetKOcaused a significant reduction in the average mIPSC 
peak amplitude when all mIPSCs were analyzed together in a cumulative histogram as 
well as when averaged among individual neurons (WT: -43 ± 4.1pA, α1HetKO: -32 ± 
2.5pA, P=0.032, Figure 5.6 C). α1HetKO also significantly increased the rise time of 
inhibitory currents (WT: 1.8 ± 0.15ms, α1HetKO: 2.4 ± 0.20ms, P=0.024).  We used a 
single exponential to fit the time course of current decay of each mIPSC to calculate the 
decay time constant, τ, for each mIPSC. We found that both when analyzed in a 
cumulative histogram and when averaged among neurons, the α1HetKO neurons 
exhibited significantly longer decay time constants (WT: 24 ± 0.9ms, α1HetKO: 27 ± 
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1.3ms, P=0.034, Figure 5.6 B). Oftentimes, GABAA receptor current decay is fit to the sum 
of two exponentials. However, it is very difficult to accurately determine when applied 
to each individual mIPSC; thus, we averaged all the mIPSC traces from each individual 
neuron and then fit the current decay to one or two exponentials and calculated the 
weighted decay time constant, τw. We found that α1HetKO neurons exhibited a 
significantly longer τw as compared to WT (WT: 12.7 ± 1.0ms, α1HetKO: 17.4 ± 1.6ms, 
P=0.024).  The changes we observed in the synaptic physiology of layer VI cortical 
neurons from α1HetKO mice are consistent with our biochemical findings of increased 
α3 subunit expression in α1HetKO mice.             
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CHAPTER VI 
DISCUSSION AND CONCLUSIONS 
β Subunit Expression 
 We found that α1HetKO reduced the expression of the β2 subunit of the GABAA 
receptor, but had no significant effect on the expression of the β3 subunit.  Given the fact 
that the α1 subunit is the most abundant GABAA receptor subunit and is expressed 
almost ubiquitously throughout the brain, it was somewhat surprising that we only 
observed a modest reduction in the expression of functional GABAA receptors as 
measured by β subunit expression. These results are consistent with the idea that 
increased expression of other α subunit isoforms may occur to compensate for the loss of 
the α1 subunit. Indeed, we showed a significant increase in both the surface and total 
expression of the α3 subunit, discussed in further detail below.  
Because we observed compensatory increases in the expression of the α3 subunit, 
this raises the intriguing possibility that the α3 subunit may preferentially assemble into 
receptors with the β3 subunit rather than with β2. This is consistent with observations 
that brain regions almost exclusively expressing α3—such as the reticular nucleus of the 
thalamus—express the β3 subunit and not the β2 subunit (Eyre 2012). Further studies 
will be required to determine if α3 does in fact preferentially assemble with β3.   
Alterations in α Subunit Expression 
 Two important findings regarding GABAA receptor α subunit expression in 
cortical neurons were revealed by these studies. First, we found that α1HetKO increased 
the surface : total expression ratio of the α1 subunit by eliciting significantly smaller 
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reductions in surface expression as compared to the reductions observed in total α1 
subunit expression. Secondly, α1HetKO increased both the total and surface expression 
of the α3 subunit. Previous reports using Western blot and immunohistochemistry 
reached conflicting conclusions regarding the effect of α1HetKO on the total expression 
of the α3 subunit. However, using semiquantitative Western blotting with linear 
detection of protein, we have demonstrated that α1HetKO does in fact increase total α3 
subunit expression in the cortex. Likewise, we have shown here that α1HetKO also 
significantly increased the expression of the α3 subunit on the cell surface which would 
be expected to alter GABAergic physiology. 
 We explored the mechanism by which these two modes of compensation could 
have occurred by first measuring the levels of WT α1 and α3 subunit mRNAs in cortices 
from WT and α1HetKO mice. These studies revealed that compensation does not occur 
at the level of transcription—there was no significant change in α3 subunit mRNA 
expression and we did not observe increased expression of α1 mRNA from the 
remaining WT allele. These data indicate a post-transcriptional mode of upregulation 
consistent with previous reports in homozygous α1 knockout mice that that neurons 
upregulate the GABAA receptor subunits they normally express rather than expanding 
their subunit repertoire (Kralic 2006). 
Next we investigated the possibility that α1HetKO reduced the baseline rate of 
endocytosis of GABAA receptors which could lead to both an increase in surface α3 
expression as well as the increased surface : total ratio of α1 expression. When treated 
with an inhibitor of dynamin-dependent endocytosis, WT neurons exhibited a time 
dependent increase in mIPSC peak amplitude while α1HetKO neurons did not display 
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any significant response. These findings could indicate that the α1HetKO neurons may 
compensate for the loss of the α1 subunit by decreasing the rate of baseline GABAA 
receptor endocytosis and thus increasing the number of GABAA receptors on the cell 
surface. Phosphorylation of various GABAA receptor subunits is known to regulate the 
rate of receptor endocytosis and surface expression. Phosphorylation of the β3 subunit 
reduces endocytosis and increases surface expression by inhibiting the interaction of the 
clathrin adapter protein AP2 with the receptor, whereas phosphorylation of the β2 
subunit via PKC enhances endocytosis and thus would be expected to reduce surface 
expression (Terunuma 2008; Saliba 2012; Herring 2005). It is possible that α1HetKO 
alters phosphorylation in such a way that facilitates reduced endocytosis and increased 
surface expression of GABAA receptors. However, further studies specifically examining 
GABAA receptor phosphorylation in the α1HetKO will be needed to address this issue. 
α1HetKO Alters Synaptic GABAergic Physiology 
 In mIPSCs recorded from α1HetKO neurons, we observed increased rise times, 
longer current decay constants, and reduced peak current amplitudes. The increase in 
rise time and the lengthening of the decay constant are consistent with the observed 
increase in surface expression of the α3 subunit. Recall from Chapter II that the 
biophysical properties of GABAA receptors are in large part dictated by their α subunit 
isoform. It is well established that α3 containing receptors activate more slowly than α1 
containing receptors and that α3 containing receptors exhibit slower decay kinetics than 
those containing α1. Additionally, α3 subunit containing GABAA receptors exhibit a 
decreased GABA EC50 as compared to those containing the α1 subunit, meaning that α3 
subunit containing GABAA receptors are less sensitive to GABA. Reduced GABA 
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sensitivity could feasibly cause the decrease in mIPSC peak current amplitude that we 
observed in the α1HetKO neurons. 
Implications for the Effects of α1HetKO in the Development of Seizures 
 Hyperexcitability in the cortex of both humans and rodents with absence 
epilepsy has been reported in neurophysiological studies (Badawy 2012; Fedi 2008; 
Lüttjohann 2011). In these studies we have demonstrated that α1HetKO mice with 
absence epilepsy displayed alterations in cortical GABAA receptor expression and 
composition as well as reduced mIPSC peak current amplitudes and increased mIPSC 
current decay times in layer VI pyramidal neurons. Recall that layer VI pyramidal 
neurons are thought to initiate absence seizures (Polack 2007). Reduced GABAergic 
current amplitudes in these neurons could lead to disinhibition in this layer and increase 
the likelihood of seizure initiation. Reduced synaptic GABAergic currents have been 
reported previously in upper cortical layers using other rodent models of absence 
epilepsy (Sasaki 2006; Tan 2007).  However, to our knowledge this is the first case 
demonstrating synaptic disinhibition in layer VI cortical neurons—those thought to be 
responsible for the initiation of absence seizures. 
 Lengthening of the decay times of GABAergic currents has not previously been 
associated with absence epilepsy. One possibility is that the increase in current decay 
times partially compensates for the reduced peak current amplitudes in the α1HetKO 
neurons by normalizing the charge transfer carried by the chloride ions. Conversely, it is 
also possible that the increase in current decay times could exacerbate seizures by 
allowing for increased de-inactivation of T-type calcium channels (Mann 2008) or by 
promoting increased neuronal synchrony. Experiments in which IPSC decay times could 
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be selectively manipulated will clarify the role of prolonged IPSC decay times in the 
development of absence seizures. 
 The changes we observed in the endocytosis and recycling of GABAA receptors 
in α1HetKO neurons could also be related to the occurrence of seizures. Previous reports 
indicated that large pharmacologically induced increases in neuronal activity lead to a 
decrease in GABAA receptor endocytosis and thus increased surface expression  
(Rannals 2011). Thus it is possible that the occurrence of absence seizures in the 
α1HetKO mice caused the reductions in endocytosis that we observed. However, the 
fact that the inhibition of dynamin-dependent endocytosis had no effect on mIPSC peak 
current amplitudes indicates that the α1HetKO neurons had maximized their ability to 
alter endocytosis. These neurons would be incapable of increasing their GABAergic 
transmission any further in response to higher frequency activity. This would also 
increase seizure susceptibility in α1HetKO mice, especially during times of high 
frequency neuronal activity. In the future, experiments designed to specifically test the 
relationship between absence seizures and alterations in GABAA receptor endocytosis 
will help determine whether the absence seizures cause a reduction in endocytosis or if 
the inability to further decrease endocytosis in response to high frequency activity 
facilitates the occurrence of seizures. It is important to note that these two possibilities 
may not be mutually exclusive: absence seizures could initially cause a reduction in 
GABAA receptor endocytosis, and once this effect is maximized, the neurons will no 
longer be able to adjust to high frequency activity which would lead to increased seizure 
susceptibility. 
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Conclusion 
In order to understand the pathophysiology behind generalized epilepsy, it is 
imperative to delineate the molecular and physiological alterations associated with the 
disorder. Although most idiopathic generalized epilepsies are thought to be multigenic 
which renders animal modeling fairly difficult, the identification of monogenic forms of 
generalized epilepsy has permitted the generation of animal models based on human 
disease associated mutations—a powerful tool for advancing our understanding of 
epilepsy. One such model, the α1HetKO mouse, has been established as a model of 
generalized absence epilepsy which is construct, face, and predictively valid (Arain 
2012). The model is based on a human genetic mutation, recapitulates the phenotype 
associated with the mutation in a mouse, and responds to the same therapeutic 
interventions used to treat human patients with absence epilepsy.  
In these studies, we discovered that α1HetKO altered both the total and surface 
expression and subunit composition of GABAA receptors in cortical neurons. Through 
our investigation of endocytosis and recycling of these receptors, we identified a 
molecular mechanism that likely contributes to the development of these changes. 
Unsurprisingly, the changes in receptor expression and makeup were accompanied by 
changes in synaptic GABAergic physiology in the α1HetKO neurons. By characterizing 
the molecular mechanisms modulating inhibitory transmission in a model of epilepsy, 
we have begun to elucidate the pathophysiology that may contribute to the paroxysmal 
development of generalized seizures.  
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